Demand for GLP-1 weight loss medications has reshaped Irish community pharmacy in the past two years. Patients are arriving at the counter armed with information, and sometimes misinformation, from social media and they are coming with questions pharmacists need to be prepared to answer confidently and accurately.
This guide covers what is approved in Ireland, what is covered under State schemes, how to manage the illegal market conversation, and how your pharmacy can position itself at the centre of this growing clinical area.
The Irish GLP-1 landscape: what’s approved and what isn’t
Not all GLP-1 medications are created equal in the eyes of Irish regulators, and this is the first confusion most patients have. Here is a quick breakdown of what is on the market and what it is approved for.
Ozempic (semaglutide): diabetes only
Despite being the medication that launched the cultural moment around ‘weight loss jabs’, Ozempic is licensed for type 2 diabetes only, not for weight management, in Ireland and worldwide. Diabetic patients may access it via the Long-Term Illness (LTI) scheme. Prescribing it off-label for weight loss is outside the licensed indication and, now that approved weight-loss alternatives exist, regulatory scrutiny has tightened.
Wegovy (semaglutide): licensed for weight management
Wegovy contains the same active ingredient as Ozempic (semaglutide) but at a higher dose and with a specific weight management licence. It is indicated for adults with a BMI (Body Mass Index) of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity. It is available on private prescription only, no State reimbursement as of 2026.
Saxenda (liraglutide): licensed and partially reimbursed
Currently, liraglutide (Saxenda) is the sole weight-loss drug eligible for reimbursement through Medical Card schemes or Drugs Payment Scheme (DPS) in Ireland. Access is strictly regulated by the HSE’s Managed Access Protocol; to qualify, patients must be adults with a BMI of at least 35 kg/m², prediabetes and an elevated risk of cardiovascular disease.
Mounjaro (tirzepatide): the newest option
Mounjaro is a dual GIP and GLP-1 receptor agonist, the first of its kind, and is now approved for weight management in Ireland. Clinical trials showed average weight loss of up to 22.5% of body weight over 72 weeks at the highest dose, making it the most effective injectable weight-loss treatment currently available.
Since Wegovy, Saxenda and Mounjaro are now formally approved for weight management, regulatory expectations have tightened, both prescribers and pharmacists are expected to adhere more strictly to licensed indications when dispensing.
Reimbursement: what your patients will ask you
The number one question pharmacists are fielding is: ‘Is this covered on my medical card?’ The short answer for most patients is no, but the situation is more nuanced than that.
Saxenda under the HSE Managed Access Protocol
As of 2026, Saxenda (liraglutide) is the only weight-loss medication reimbursed under the Drugs Payment Scheme (DPS) or Medical Card (GMS) scheme in Ireland. Reimbursement is available only under a Managed Access Protocol for a tightly defined patient group:
- BMI of 35 kg/m² or above
- Diagnosed with prediabetes (fasting plasma glucose 5.5–6.9 mmol/L and HbA1c 42-47 mmol/mol)
- High cardiovascular risk (total cholesterol > 5 mmol/L or mean systolic BP > 140 mmHg)
- Actively participating in a non-pharmacological weight management intervention
Reimbursement is approved in two phases. Phase 1 grants six months of coverage. For Phase 2 to be approved, the patient must have lost at least 5% of their initial body weight after 12 weeks on the full 3 mg daily dose. Total reimbursement support is limited to two years.
The prescriber submits the application through an online portal linked to the PCRS claims system. Pharmacies can check and confirm approval status through the Secure Scheme Checker under ‘Patient Specific Arrangements’ in Pharmacy Suite.
Wegovy and Mounjaro: private prescription only (for now)
Wegovy and Mounjaro are not currently reimbursed on State schemes for weight management. Patients pay privately, with costs typically ranging from €150 to €300+ per month depending on dose and supplier. Mounjaro’s NCPE reimbursement review, expected in 2026, may change the picture, it is considered a stronger candidate than Wegovy, given greater efficacy and a different active ingredient to Ozempic.
The illegal market: a growing crisis and a pharmacy opportunity
The high cost and high demand for GLP-1 medications has created a thriving illegal market and patients are at real risk. This is one of the most important conversations pharmacists can be having right now.
The HPRA’s figures for 2025 are striking. The number of illegal GLP-1 products detained surged from 1,582 individual packages in 2024 to 48,752 in 2025, a 30-fold increase. Overall, more than 750,000 units of illicit medicines were seized during the year. Individual consignments linked to personal purchases rose by 180% year on year.
The products seized were predominantly marketed as GLP-1 drops (27,329 items) or transdermal microneedle patches (17,170 items). Despite the claims on their packaging, HPRA testing confirmed that the patches did not contain semaglutide at all. Neither drops nor patches are authorised forms of GLP-1 medication, there is no clinical evidence supporting their use.
The HPRA has been unequivocal: «sourcing prescription medicines outside of a registered pharmacy and without appropriate medical supervision poses a significant risk to your health.» Products obtained through unregulated channels cannot be assured for quality, safety or origin.
For pharmacists, this is both a patient safety imperative and a business opportunity. When a patient mentions they have seen GLP-1 drops on Instagram or are considering buying from an online source, that is the moment to explain, clearly and without judgment, why the registered pharmacy is the only safe route. You can report suspicious activity to the HPRA at reportacase@hpra.ie or 01 634 3871.
Stock management: what pharmacists need to know
Supply of GLP-1 medications has been unpredictable, though shortages have eased since mid-2025. Pharmacies should be aware of a few practical realities:
- Cold-chain storage is required: all GLP-1 injectable pens must be stored at 2-8°C. Once in use, Mounjaro pens can be stored below 30°C for up to 30 days; always advise patients on this at the point of dispensing.
- Titration schedules matter: patients start on low doses and escalate weekly or monthly. Coordinate with prescribers to ensure supply aligns with the titration plan, especially during the early months of treatment.
- Sharps disposal: remind patients to return used pens to the pharmacy or a local council collection point. This is both a legal obligation and a patient care touchpoint.
- Communicate shortages proactively: if a product is unavailable, contact the prescriber early so an alternative can be considered rather than leaving the patient without treatment.
Patient counselling: what to cover at the counter
Community pharmacists are ideally placed to support GLP-1 patients through their treatment journey, from injection technique to side effect management. These are the key points to cover:
Managing side effects
The most common side effects are nausea, vomiting, diarrhoea and constipation, particularly in the early weeks of treatment. These typically ease as the dose is gradually increased.
Advise patients to:
- Eat smaller, more frequent meals and stop eating when comfortably full
- Sip fluids between meals rather than during, to reduce nausea
- Choose low-fat, high-fibre foods and avoid fatty or fried meals during the adjustment period
- Stay well hydrated, especially if experiencing vomiting or diarrhoea
Contact their GP if symptoms persist for more than a few days or feel severe.
Injection technique and site rotation
GLP-1 pens are injected into the abdomen, thigh or upper arm. Patients should rotate the exact area of injection each week to avoid skin irritation or lipohypertrophy. Demonstrate technique and check understanding at the first dispense.
Drug interactions
GLP-1 medications slow gastric emptying, which can affect the absorption of oral medications, particularly oral contraceptives and thyroid medications. A thorough medicines reconciliation is important before and during treatment. Patients should inform their pharmacist of any new medications started during GLP-1 therapy.
Why GLP-1 matters for your pharmacy
GLP-1 demand is a sustained shift in how obesity is treated. For Irish independent pharmacies, this represents one of the most significant clinical and commercial opportunities in years.
Patients on GLP-1 therapy return monthly for refills, require ongoing counselling, need monitoring support and are often managing related conditions like hypertension, dyslipidaemia or prediabetes. A single GLP-1 patient can represent a meaningful long-term relationship with your pharmacy.
Beyond the prescription itself, pharmacies with visible online presence are winning new GLP-1 patients from delivery platforms and local search. Patients are actively searching for pharmacies that stock these medications and that can offer informed advice. Positioning your pharmacy, both in person and online, as a knowledgeable, safe, and convenient GLP-1 resource is a real competitive advantage.
One way to strengthen that online presence is through delivery apps. LUDA Partners connects Irish community pharmacies to Uber Eats, Just Eat and Deliveroo through a single integration, handling catalogue setup, updates and optimisation, with no fixed fees and minimal workload for your team. While prescription medicines including GLP-1 injectables cannot be sold via delivery apps, the patients seeking them are exactly the health-conscious, digitally active customers likely to order vitamins, supplements, health monitors and beauty products online. A pharmacy that is visible and easy to order from is better placed to become their go-to for everything else too.
Want to make your pharmacy more visible to the patients already searching for health products online? LUDA Partners helps Irish pharmacies sell on Uber Eats, Just Eat and Deliveroo with no fixed fees and no added workload. Find out how it works.
The HPRA’s crackdown on illegal online suppliers reinforces this message: the registered community pharmacy is the only place patients can be certain of what they are getting.
Key takeaways for Irish pharmacists
- Ozempic is for type 2 diabetes only, not weight loss. Wegovy, Saxenda and Mounjaro are the licensed weight-management options.
- Only Saxenda is reimbursed under State schemes, and only for patients with BMI ≥35, prediabetes and high cardiovascular risk, under a strict HSE Managed Access Protocol.
- Illegal GLP-1 drops and patches flooded the Irish market in 2025: HPRA testing confirmed they often contained no semaglutide. Patients must be directed to licensed pharmacies only.
- Side effect counselling, injection technique, drug interactions and sharps disposal are all pharmacist responsibilities and patient touchpoints.
- GLP-1 therapy represents a long-term patient relationship and a growing business opportunity for community pharmacies.